These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38665828)

  • 1. Discovery of novel positive allosteric modulators targeting GluN1/2A NMDARs as anti-stroke therapeutic agents.
    Zhu H; Chen X; Zhang L; Liu X; Chen J; Zhang HT; Dong M
    RSC Med Chem; 2024 Apr; 15(4):1307-1319. PubMed ID: 38665828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel GluN2A NMDAR positive allosteric modulators via scaffold hopping strategy as anti-stroke therapeutic agents.
    Chen X; Zhu H; Liu X; Li Q; Dong M
    Bioorg Med Chem; 2023 Apr; 83():117236. PubMed ID: 36934527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects.
    Vizi ES; Kisfali M; Lőrincz T
    Brain Res Bull; 2013 Apr; 93():32-8. PubMed ID: 23089362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GluN2A Subunit-Containing NMDA Receptors Are the Preferential Neuronal Targets of Homocysteine.
    Sibarov DA; Abushik PA; Giniatullin R; Antonov SM
    Front Cell Neurosci; 2016; 10():246. PubMed ID: 27847466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function.
    Hackos DH; Lupardus PJ; Grand T; Chen Y; Wang TM; Reynen P; Gustafson A; Wallweber HJ; Volgraf M; Sellers BD; Schwarz JB; Paoletti P; Sheng M; Zhou Q; Hanson JE
    Neuron; 2016 Mar; 89(5):983-99. PubMed ID: 26875626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein Kinase C-Mediated Phosphorylation and α2δ-1 Interdependently Regulate NMDA Receptor Trafficking and Activity.
    Zhou MH; Chen SR; Wang L; Huang Y; Deng M; Zhang J; Zhang J; Chen H; Yan J; Pan HL
    J Neurosci; 2021 Jul; 41(30):6415-6429. PubMed ID: 34252035
    [No Abstract]   [Full Text] [Related]  

  • 7. Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.
    Warikoo N; Brunwasser SJ; Benz A; Shu HJ; Paul SM; Lewis M; Doherty J; Quirk M; Piccio L; Zorumski CF; Day GS; Mennerick S
    J Neurosci; 2018 Mar; 38(13):3218-3229. PubMed ID: 29476014
    [No Abstract]   [Full Text] [Related]  

  • 8. Distinct GluN1 and GluN2 Structural Determinants for Subunit-Selective Positive Allosteric Modulation of
    Strong KL; Epplin MP; Ogden KK; Burger PB; Kaiser TM; Wilding TJ; Kusumoto H; Camp CR; Shaulsky G; Bhattacharya S; Perszyk RE; Menaldino DS; McDaniel MJ; Zhang J; Le P; Banke TG; Hansen KB; Huettner JE; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2021 Jan; 12(1):79-98. PubMed ID: 33326224
    [No Abstract]   [Full Text] [Related]  

  • 9. Involvement of the GluN2A and GluN2B subunits in synaptic and extrasynaptic N-methyl-D-aspartate receptor function and neuronal excitotoxicity.
    Zhou X; Ding Q; Chen Z; Yun H; Wang H
    J Biol Chem; 2013 Aug; 288(33):24151-9. PubMed ID: 23839940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of GluN2A and GluN2B gain-of-function epilepsy mutations on synaptic currents mediated by diheteromeric and triheteromeric NMDA receptors.
    Chen X; Keramidas A; Harvey RJ; Lynch JW
    Neurobiol Dis; 2020 Jul; 140():104850. PubMed ID: 32247039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric Interactions between NMDA Receptor Subunits Shape the Developmental Shift in Channel Properties.
    Sun W; Hansen KB; Jahr CE
    Neuron; 2017 Apr; 94(1):58-64.e3. PubMed ID: 28384476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights into assembly and function of GluN1-2C, GluN1-2A-2C, and GluN1-2D NMDARs.
    Chou TH; Kang H; Simorowski N; Traynelis SF; Furukawa H
    Mol Cell; 2022 Dec; 82(23):4548-4563.e4. PubMed ID: 36309015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional coupling of TRPM2 and extrasynaptic NMDARs exacerbates excitotoxicity in ischemic brain injury.
    Zong P; Feng J; Yue Z; Li Y; Wu G; Sun B; He Y; Miller B; Yu AS; Su Z; Xie J; Mori Y; Hao B; Yue L
    Neuron; 2022 Jun; 110(12):1944-1958.e8. PubMed ID: 35421327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restored Fyn Levels in Huntington's Disease Contributes to Enhanced Synaptic GluN2B-Composed NMDA Receptors and CREB Activity.
    Fão L; Coelho P; Rodrigues RJ; Rego AC
    Cells; 2022 Sep; 11(19):. PubMed ID: 36231023
    [No Abstract]   [Full Text] [Related]  

  • 15. TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner.
    Edman S; McKay S; Macdonald LJ; Samadi M; Livesey MR; Hardingham GE; Wyllie DJ
    Neuropharmacology; 2012 Sep; 63(3):441-9. PubMed ID: 22579927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of N-acetyl-aspartyl-glutamate on synaptic and extrasynaptic NMDA receptors are subunit- and pH-dependent in the CA1 region of the mouse hippocampus.
    Khacho P; Wang B; Ahlskog N; Hristova E; Bergeron R
    Neurobiol Dis; 2015 Oct; 82():580-592. PubMed ID: 26303888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease.
    Yu SP; Jiang MQ; Shim SS; Pourkhodadad S; Wei L
    Mol Neurodegener; 2023 Jul; 18(1):43. PubMed ID: 37400870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palmitoylation Controls NMDA Receptor Function and Steroid Sensitivity.
    Hubalkova P; Ladislav M; Vyklicky V; Smejkalova T; Hrcka Krausova B; Kysilov B; Krusek J; Naimová Z; Korinek M; Chodounska H; Kudova E; Cerny J; Vyklicky L
    J Neurosci; 2021 Mar; 41(10):2119-2134. PubMed ID: 33526476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of a novel negative allosteric modulator of NMDA receptors, UBP792.
    Sapkota K; Burnell ES; Irvine MW; Fang G; Gawande DY; Dravid SM; Jane DE; Monaghan DT
    Neuropharmacology; 2021 Dec; 201():108818. PubMed ID: 34610288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 7-Methoxyderivative of tacrine is a 'foot-in-the-door' open-channel blocker of GluN1/GluN2 and GluN1/GluN3 NMDA receptors with neuroprotective activity in vivo.
    Kaniakova M; Kleteckova L; Lichnerova K; Holubova K; Skrenkova K; Korinek M; Krusek J; Smejkalova T; Korabecny J; Vales K; Soukup O; Horak M
    Neuropharmacology; 2018 Sep; 140():217-232. PubMed ID: 30099049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.